Home About us Contact
|
Home About us Contact | ||
|
|
||
One Antibody (one + antibody)
Selected AbstractsDevelopment and characterization of a monoclonal antibody against Taura syndrome virusJOURNAL OF FISH DISEASES, Issue 12 2009I Côté Abstract We produced a panel of monoclonal antibodies (MAbs) from the fusion of Taura syndrome virus variants from Belize (TSV-BZ) immunized BALB/cJ mouse spleen cells and non-immunoglobulin secreting SP2/0 mouse myeloma cells. One antibody, 2C4, showed strong specificity and sensitivity for TSV in dot-blot immunoassay and immunohistochemistry (IHC) analysis. The MAb reacted against native TSV-BZ, TSV variants from Sinaloa, Mexico (TSV-SI) and TSV variants from Hawaii (TSV-HI) in dot-blot immunoassay. By IHC, the antibody identified the virus in a pattern similar to the digoxigenin-labelled TSV-cDNA probe for the TSV-BZ, TSV-HI and TSV-SI variants, but not for the TSV variants from Venezuela (TSV-VE) and the TSV variants from Thailand (TSV-TH). MAb 2C4 did not react against other shrimp pathogens or with normal shrimp tissue. Western blot analysis showed a strong reaction against CP2, a region of high antigenic variability amongst TSV variants. This antibody has potential diagnostic application in detection and differentiation of certain TSV biotypes. [source] Antikörper-Nachweis bei invasiver AspergilloseMYCOSES, Issue 2004R. Kappe Aspergillus; aspergillosis; invasive infection; antibody detection Zusammenfassung Der Stellenwert von Aspergillus -Antikörpertesten zur Diagnostik der invasiven Aspergillose (IA) ist unklar. In zwei Studien wurden drei verschiedene Antikörperteste an Patienten mit gesicherter IA evaluiert: (i) kommerzieller Hämagglutinationstest (HAT), (ii) kommerzieller Enzymimmunoassay (EIA) IgG, IgM, IgA und (iii) ein experimenteller Mitogillin EIA IgG, IgM, IgA. In der ersten Studie wurden 99 Serumproben von 26 Patienten mit IA und 22 Serumproben von 22 Kontrollpatienten mit allen drei Tests untersucht. 10 von 26 Patienten (38%) waren in mindestens einem Antikörpertest positiv. Die höchste Sensitivität wies der IgG-Nachweis in beiden EIA-Tests auf (22 bzw. 21%), der HAT erreichte eine Sensitivität von 8%. IgM-Antikörper wurden nur bei zwei Patienten, IgA-Antikörper bei keinem Patienten nachgewiesen. Die Spezifität des HAT betrug 85%, des IgG-EIA 72%. Bei zwei Patienten mit gesicherter bzw. wahrscheinlicher IA war der Antikörpernachweis der einzig positive Labortest. In der zweiten Studie wurden retrospektiv die Ergebnisse von 60 Patienten mit gesicherter IA untersucht. 14 Patienten (23%) wiesen einen positiven Antikörpernachweis im EIA und/oder HAT auf. Die Untersuchung des zeitlichen Verlaufs der Antikörper zeigte, daß die IgG-Antikörperbildung bei immunsupprimierten Patienten durchschnittlich 10,8 Tage nach der Diagnosestellung der IA einsetzte. Schlußfolgerungen Aspergillus -Antikörper waren bei ca. 23% der Patienten mit invasiver Aspergillose nachweisbar. Die Antikörperbildung setzte bei erfolgreich therapierten immunsupprimierten Patienten durchschnittlich 10,8 Tage nach Beginn der Infektion ein. Insbesondere der IgG-Antikörpernachweis im EIA-Format kann hilfreich für die Diagnose-Sicherung und Verlaufskontrolle sein. Summary The clinical significance of Aspergillus antibody assays for the diagnosis of invasive aspergillosis (IA) is unclear. In two studies, three different antibody assays were evaluated with patients suffering from proven IA: (i) a commercial haemagglutination test (HAT), (ii) a commercial enzyme immunoassay (EIA) for IgG, IgM, and IgA, and (iii) an experimental mitogillin enzyme immunoassay for IgG, IgM, and IgA. In the first study, 99 serum samples from 26 patients with IA and 22 serum samples from 22 control patients were tested with all the three tests. Ten of the 26 patients (38%) reacted positively in at least one antibody assay. The highest sensitivity was generated by the detection of IgG using the EIA formats (22 and 21%, respectively), the HAT had a sensitivity of 8%. IgM type antibodies were detected in only two patients; no IgA type antibodies were detected. The specificities of the IgG EIA and the HAT were 72 and 85%, respectively. Antibody detection was the single positive laboratory test in two patients with proven and probable IA. In the second study, antibody test results of 60 patients with proven IA were retrospectively evaluated. Fourteen patients (23%) tested positive in the EIA and/or in the HAT. Investigations of the antibody levels in individual immunocompromised patients over time revealed that IgG production started after a mean of 10.8 days after diagnosis of IA. To conclude, antibodies against Aspergillus were detected in 23% of patients with IA. The antibody production started in successfully treated immunosuppressed patients after a mean of 10.8 days after the onset of infection. In particular, the detection of IgG-antibodies with an EIA can be useful for the confirmation of the diagnosis of IA and for the monitoring of the treatment of IA. [source] The Construction of a Functional Photoactivatable Cancer Targeting Bispecific Antibody ConjugateCHEMMEDCHEM, Issue 8 2007Stephen Thompson Dr. Masked Invader: we constructed a "cloaked" bispecific antibody conjugate in which only one antibody is initially biologically active. The other antibody is rendered inert with a coating of photolabile 2-nitrobenzyl groups until its activity is restored on irradiation with UV-A light. Such activatable conjugates could be used to target enzymes and drugs to tumours whilst minimising side effects in the rest of the body. [source] Using radioligand-binding assays to measure tissue transglutaminase autoantibodies in young childrenACTA PAEDIATRICA, Issue 8 2004D Agardh Aim: To measure autoantibodies against tissue transglutaminase (tTG) in young children prospectively screened for coeliac disease (CD). Methods: In total, 652 children aged 2.9 (2.5,4.2) y were analysed for IgA-tTG and IgG-tTG with radioligand-binding assays and IgA endomysial antibodies (EMA) by indirect immunofluorescence. Antibody-positive children were retested after 1.2 (range 0.2,1.9) y. Intestinal biopsy was performed on children with persistently high antibody levels. Results: In total, 3.2% (95% CI: 1.9,4.6%) of the 652 children were positive for at least one antibody at baseline: 2.5% (95% CI: 1.3,3.7%) for IgA-tTG, 1.7% (95% CI: 0.7,2.7%) for IgG-tTG and 2.9% (95% CI: 1.6,4.2%) for IgA-EMA, respectively. Ten children were positive for all three antibodies, five for both IgA-tTG and EMA, four for EMA only, one for IgA-tTG and another for IgG-tTG. IgA-EMA titres correlated with IgA-tTG levels (r= 0.73, p= 0.0003). At follow-up, seven of 20 children remained positive for all three antibodies, three for IgA-tTG only, one for both IgA-tTG and EMA, one for IgA-tTG and IgG-tTG, and the remaining child refused further participation. Three biopsies showed villous atrophy, two increased intraepithelial lymphocytes and two normal findings. Biopsy was not performed in four children with low or declining tTG antibody levels at follow-up and in one child who declined. CD was evident in 0.5% (95% CI: 0.0,1.0%) (3/652). Conclusion: This study revealed a high number of young children positive for tTG antibodies as well as EMA, but the majority showed declining levels in both antibodies over time. We suggest using radioligand-binding assays for quantitative measurement of tTG antibodies when change in antibody levels is studied in young children. [source] | ||||||||||